|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.
100 项与 Indalo Therapeutics, Inc. 相关的临床结果
0 项与 Indalo Therapeutics, Inc. 相关的专利(医药)
100 项与 Indalo Therapeutics, Inc. 相关的药物交易
100 项与 Indalo Therapeutics, Inc. 相关的转化医学